Alnylam Pharmaceuticals, Inc. vs Diageo plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Diageo plc trades at $94.95 (market cap $53.05B). The key difference: Diageo plc is the larger of the two by market cap, and Diageo plc pays a 3.5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | DEO | |
|---|---|---|
Market Cap | $29.60B | $53.05B |
Sector | Health | Technology |
52-Week High | $491.22 | $115.33 |
52-Week Low | $205.48 | $72.47 |
Enterprise Value | $27.56B | $72.54B |
Dividend Yield | — | 3.5% |
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Diageo (DEO) trades at $93.96, down 3.24% today, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company reported FY2026 results with organic sales declining 2% but operating profit increasing 2% through cost savings. Recent news highlights a $1 billion cost-cutting plan and strategic reset under new CEO Dave Lewis, driving investor optimism despite North American weakness.
The outlook remains cautiously optimistic with analyst consensus leaning buy (49%) as cost savings and cash generation initiatives offset regional challenges. Key risks include persistent North American sales pressure and execution risks on the turnaround plan, while valuation metrics suggest premium pricing relative to historical levels.
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →